Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 08, 2022 18:00 ET | Source: Intercept Pharmaceuticals, Inc.

New Study Published in The American Journal of Pathology Suggests Obeticholic Acid (OCA) May Improve Cognitive Impairment Associated with Cholestatic Liver Disease

MORRISTOWN, N.J., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
November 22, 2022 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals to Participate in Piper Sandler’s 34th Annual Healthcare Conference on December 1, 2022

MORRISTOWN, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
November 07, 2022 18:55 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

First-in-human data shared at The Liver Meeting® 2022 supported a favorable safety and tolerability profile for INT-787 in healthy adults Company announces severe alcohol-associated hepatitis (sAH),...
November 07, 2022 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Announces Additional Positive Data in Fibrosis due to NASH from New Analysis of Phase 3 REGENERATE Study at AASLD The Liver Meeting® 2022

OCA 25 mg demonstrated double the response rate of placebo in reduction of liver fibrosis without worsening of NASH; consistent antifibrotic effect shown across multiple analyses OCA 25 mg showed...
November 06, 2022 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Efficacy of OCA vs. placebo and external controls accepted as a late-breaker poster HEROES-US data to be presented in oral session on Sunday, November 6 MORRISTOWN, N.J., Nov. 06, 2022 (GLOBE...
November 01, 2022 07:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

U.S. Ocaliva® net sales of $77.6 million; 16.4% growth over the prior year quarter Company increases 2022 Ocaliva non-GAAP adjusted net sales guidance to $340 million to $350 million and narrows...
October 31, 2022 16:05 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting® 2022

Data from Phase 3 REGENERATE study supporting positive benefit-risk profile of obeticholic acid (OCA) in liver fibrosis due to NASH to be featured in late-breaker podium presentation Analysis...
October 25, 2022 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Announce Third Quarter 2022 Financial Results on November 1, 2022

MORRISTOWN, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
October 12, 2022 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals to Participate in H.C. Wainwright’s 6th Annual NASH Investor Conference on October 17, 2022

MORRISTOWN, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
September 30, 2022 07:55 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint

MORRISTOWN, N.J., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel...